Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis

K Hartery^{1

2}, S O'Reilly^{1

2}, D Houlihan^{2

3}, G Doherty^{1

2}, H Mulcahy^{1

2}, G Cullen^{1

2}, J Sheridan^{1

2}

Affiliations

¹ Department of Gastroenterology, Centre for Colorectal Disease, St. Vincent's University Hospital, Dublin, Ireland.
² School of Medicine, University College Dublin, Dublin, Ireland.
³ National Liver Unit, St. Vincent's University Hospital, Dublin, Ireland.

Comment

K Hartery et al. Aliment Pharmacol Ther. 2017 Jan.

. 2017 Jan;45(2):376-378.

doi: 10.1111/apt.13861.

K Hartery^{1

2}, S O'Reilly^{1

2}, D Houlihan^{2

3}, G Doherty^{1

2}, H Mulcahy^{1

2}, G Cullen^{1

2}, J Sheridan^{1

2}

¹ Department of Gastroenterology, Centre for Colorectal Disease, St. Vincent's University Hospital, Dublin, Ireland.
² School of Medicine, University College Dublin, Dublin, Ireland.
³ National Liver Unit, St. Vincent's University Hospital, Dublin, Ireland.

No abstract available

Comment on

Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C. Stallmach A, et al. Aliment Pharmacol Ther. 2016 Dec;44(11-12):1199-1212. doi: 10.1111/apt.13813. Epub 2016 Oct 7. Aliment Pharmacol Ther. 2016. PMID: 27714831